Mumbai: Indian healthcare workers have shown a high immune response to Covid after receiving the two mandated doses of both domestically manufactured vaccines —Covishield and Covaxin.
However, the study, which has not yet been peer-reviewed but was published in Medrxiv on 2 June, observed that the immune responses in 515 healthcare workers and found that 95 per cent showed seropositivity after the two doses of both vaccines.
“Of the 425 Covishield and 90 Covaxin recipients, 98.1% and 80.0% respectively, showed seropositivity,” said the study, adding that the “median interquartile rise” in anti-spike antibodies was also “significantly higher in Covishield vs Covaxin recipient” at 127 AU/mL and 53.0 AU/mL respectively.
“Both vaccines showed good and similar immune responses even after a single dose in people who already had Covid in the past. This suggests both vaccines work well,” said Awadesh Kumar Singh, lead author of the study and consultant endocrinologist, G.D. Hospital and Diabetes Institute, Kolkata.
“It, however, appears that Covishield may have a greater ability to produce more anti spike antibodies and higher seropositivity rate,” he added.
He further said, “We could also produce some real-world evidence to show that Covaxin induces good protective antibodies after the two doses in the absence of published Phase 3 data at the moment. Covishield has already published its Phase 3 data.”
Meanwhile, the rates of Vaccines are followed as the Serum Institute is providing a Covishield dose for Rs 300 to the state governments and Rs 600 to private hospitals.
The Bharat Biotech has fixed the price of a Covaxin dose at Rs 400 for states and Rs 1200 for private markets.
Follow us on Twitter, Instagram, and like us on Facebook for the latest updates and interesting stories.
